Two medicines, side by side
Eletriptan vs rizatriptan
Eletriptan and rizatriptan are both labeled for migraine. Drugs@FDA records approvals of eletriptan since 2002 and of rizatriptan since 1998. Pharmacies paid $1.75 per eletriptan hbr 40 mg tablet and $0.335 per rizatriptan 10 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. How each works, in its label's words: Eletriptan, “Eletriptan binds with high affinity to 5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors.”; Rizatriptan, “Rizatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors.”
Check it at the source: the eletriptan FDA label on DailyMed (effective November 27, 2024); the rizatriptan FDA label on DailyMed (effective January 29, 2026).
Highlights of the eletriptan record
Eletriptan (Relpax) · label of November 27, 2024
Used for
From the label: indicationsEletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. […]
On the market
- Earliest approval on file
- December 26, 2002
- Generic labelers
- 10 labelers
- Pharmacy cost
- $1.75 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the rizatriptan record
Rizatriptan (Maxalt) · label of January 29, 2026
Used for
From the label: indicationsMAXALT ® and MAXALT-MLT ® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use MAXALT should only be used where a clear diagnosis of migraine has been established. […]
On the market
- Earliest approval on file
- June 29, 1998
- Generic labelers
- 22 labelers
- Pharmacy cost
- $0.335 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 9
Source: FDA drug labels via openFDA (Eletriptan label of November 27, 2024, Rizatriptan label of January 29, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do eletriptan and rizatriptan differ on the record?
How each works, in its label's words: Eletriptan, “Eletriptan binds with high affinity to 5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors.”; Rizatriptan, “Rizatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors.”
Both are in FDA's class serotonin-1b and serotonin-1d receptor agonists.
Half-life, in each label's words: Eletriptan, “Elimination: The terminal elimination half-life of eletriptan is approximately 4 hours.”; Rizatriptan, “The plasma half-life of rizatriptan in males and females averages 2-3 hours.”
Generics: eletriptan since 2017; rizatriptan since 2012 (Drugs@FDA).
| Eletriptan | Rizatriptan | |
|---|---|---|
| Labeled for | Migraine | Migraine |
| Pharmacologic class | Serotonin-1b and Serotonin-1d Receptor Agonist | Serotonin-1b and Serotonin-1d Receptor Agonist |
| How it works (label) | Eletriptan binds with high affinity to 5-HT 1B , 5-HT 1D and 5-HT 1F receptors, has modest affinity for 5-HT 1A , 5-HT 1E , 5-HT 2B and 5-HT 7 receptors. | Rizatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. |
| Half-life (label) | Elimination: The terminal elimination half-life of eletriptan is approximately 4 hours. | The plasma half-life of rizatriptan in males and females averages 2-3 hours. |
| Earliest approval on file (Drugs@FDA) | December 26, 2002 | June 29, 1998 |
| First generic approved | June 16, 2017 | December 31, 2012 |
| Generic labelers (NDC) | 10 labelers | 22 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $1.75 per tablet (Eletriptan hbr 40 mg tablet) | $0.335 per tablet (Rizatriptan 10 mg tablet) |
| 12-month price change | -15% | -34% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 9 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,996 | 16,132 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to eletriptan
- every medicine labeled for the same conditions